Julian Grandvallet-Contreras
Cancer genomics, epigenomics, and pipelines that can be checked.
Division of Hematology, Oncology and Bone Marrow Transplant
University of Colorado
Anschutz Medical Campus
I am a bioinformatics analyst at the University of Colorado Anschutz Medical Campus, embedded in a multi-PI shared resource in the Department of Pediatrics. My work runs across germline and somatic variant analysis, bulk and single-cell RNA-seq, ATAC-seq and CUT&RUN, applied mostly to childhood leukemia, neuro-oncology and cancer evolution.
Most of what I do is building analysis that other people can rely on and reproduce. That means containerized Nextflow pipelines on HPC for six laboratories, written records of the decisions behind duplicate handling and normalization and filtering, and where it matters, a second independent implementation to check the first one. A recent benchmark found that the standard normalization method reports a real fourfold loss of signal as a significant gain, which is the kind of result you only find if you go looking.
I work in R and Python, on nf-core and Nextflow, in the Bioconductor and tidyverse ecosystems. I also teach: an asynchronous R course for researchers, four mentored trainees, and an invited faculty workshop at AACR on using large language models for scientific programming.
Co-author on work in the New England Journal of Medicine, Leukemia, EBioMedicine, Brain Pathology and Blood. Originally from Mexico City, currently in Colorado, and happy to hear from people working on genomics anywhere.
selected publications
- Circulating gastric cancer stem cells as blood screening and prognosis factor in gastric cancerStem Cells International, 2024
- A naturally occurring gain-of-function mutation in factor VIIINew England Journal of Medicine, 2025
- Lipid uptake via FATP2 enhances CAR-t therapy resistance in B-cell acute lymphoblastic leukemiaBlood, 2025
- FATP2-mediated lipid metabolism enhances chimeric antigen receptor T-cell therapy resistance in B-cell acute lymphoblastic leukemiaLeukemia, 2026
- Quantifying rate-limiting genetic variation in breast and ovarian tumourigenesisEBioMedicine, 2026